This program focuses on dissemination of emerging clinical evidence and comprehensive oral and intravenous pharmacotherapy management strategies. The exponential growth of therapies, along with the increased utilization of multiple lines of therapies call for close oversight of rapidly expanding therapeutic options. In addition, advances in diagnostics expanding precision medicine modalities increasingly guide individualized therapy options. With vast emerging scientific evidence on all fronts, it is essential for pharmacists to be equipped with cutting-edged education on evidenced-based treatment options for their patients. This summit also focuses on identifying best practices addressing the unique challenges and opportunities in the local market of Minneapolis, aiming to leverage patient access to therapies while driving efficiencies and value for all stakeholders involved. The summit gathers subject matter experts to highlight clinical and practical considerations for emerging specialty pharmaceuticals in a wide variety of oncology and malignant hematology conditions, as well as breakthrough pharmacotherapy advancements in other specialties such as neurology and endocrinology. The content emphasizes the importance and role of the pharmacists in patient adherence. Validated monitoring and adherence tools will be shared as avenues to best manage optimal therapy outcomes. Furthermore, expert panels will identify potential avenues to drive value through utilization of biosimilars, 505(b)(2) products and other emerging drug classes. Clinical and practical considerations will focus on the challenges and opportunities facing the ecosystem of stakeholders (e.g., patient, pharmacy, payer, manufacturer) that collectively establish access to specialty pharmaceuticals. Target Audience & Expected Attendance This educational activity has been designed to meet the educational needs of all pharmacy professionals, including pharmacists and pharmacy technicians. Expected attendance: 120 professionals. Learner Objectives Upon completion of this activity, participants should be able to: Identify emerging specialty pharmacotherapy options Discuss therapy management and monitoring considerations Recognize strategies to drive optimal therapy outcomes Distinguish strategies to drive multi-stakeholder efficiencies and value

Thank you for attending this conference.  Your feedback is valuable to us.

To receive your Certificate of Attendance, complete and submit the Evaluation Form. Once this form is submitted your certificate will be available for download.

Registered attendees can earn a maximum of 7.25 CPE credits, depending on sessions attended as noted below by day. You will be able to select the amount of credits being claimed.

• Day 1 (Sept. 12): 2.50

• Day 2 (Sept. 13): 4.75

• Total: 7.25 Credits

Pharmacists: In order for MEC to report your pharmacy credits, your NABP e-Profile number and date of birth (mm/dd/yyyy) MUST be included in your MyMedflix user profile. Your CE credits will be electronically submitted to CPE Monitor^® within 60 days upon successful completion of the activity evaluation.

For questions regarding credit for this activity, please contact MEC at info@meccinc.com. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.